Lotus Ventures Past Earnings Performance
Past criteria checks 0/6
Lotus Ventures's earnings have been declining at an average annual rate of -19.3%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 20.7% per year.
Key information
-19.3%
Earnings growth rate
-7.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 20.7% |
| Return on equity | -20.5% |
| Net Margin | -93.7% |
| Last Earnings Update | 31 Aug 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Lotus Ventures makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 23 | 2 | -2 | 1 | 0 |
| 31 May 23 | 2 | -6 | 1 | 0 |
| 28 Feb 23 | 2 | -6 | 1 | 0 |
| 30 Nov 22 | 1 | -6 | 1 | 0 |
| 31 Aug 22 | 2 | -5 | 1 | 0 |
| 31 May 22 | 2 | 0 | 1 | 0 |
| 28 Feb 22 | 3 | 0 | 1 | 0 |
| 30 Nov 21 | 5 | 1 | 1 | 0 |
| 31 Aug 21 | 5 | 0 | 2 | 0 |
| 31 May 21 | 6 | 0 | 2 | 0 |
| 28 Feb 21 | 6 | 1 | 2 | 0 |
| 30 Nov 20 | 6 | 0 | 2 | 0 |
| 31 Aug 20 | 5 | 1 | 1 | 0 |
| 31 May 20 | 3 | 1 | 1 | 0 |
| 29 Feb 20 | 1 | -1 | 2 | 0 |
| 30 Nov 19 | 0 | -1 | 2 | 0 |
| 31 Aug 19 | 0 | -3 | 3 | 0 |
| 31 May 19 | 0 | -2 | 2 | 0 |
| 28 Feb 19 | 0 | -3 | 3 | 0 |
| 30 Nov 18 | 0 | -3 | 3 | 0 |
| 31 Aug 18 | 0 | -3 | 2 | 0 |
| 31 May 18 | 0 | -2 | 2 | 0 |
| 28 Feb 18 | 0 | -2 | 2 | 0 |
| 30 Nov 17 | 0 | -1 | 1 | 0 |
| 31 Aug 17 | 0 | -1 | 1 | 0 |
| 31 May 17 | 0 | -1 | 1 | 0 |
| 28 Feb 17 | 0 | -1 | 1 | 0 |
| 30 Nov 16 | 0 | -1 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | -1 | 1 | 0 |
| 29 Feb 16 | 0 | -1 | 1 | 0 |
| 30 Nov 15 | 0 | -1 | 1 | 0 |
| 31 Aug 15 | 0 | -1 | 0 | 0 |
| 31 May 15 | 0 | -1 | 0 | 0 |
Quality Earnings: LV9 is currently unprofitable.
Growing Profit Margin: LV9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LV9 is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare LV9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LV9 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.8%).
Return on Equity
High ROE: LV9 has a negative Return on Equity (-20.54%), as it is currently unprofitable.